Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Vitamin D and prostate cancer risk: a review of the epidemiological literature

Abstract

Prostate cancer is the most commonly diagnosed cancer in the United States. Prostate cells contain vitamin D receptors as well as enzymes necessary for vitamin D metabolism. Vitamin D metabolites have an antiproliferative and a pro-differentiating effect on prostate cancer cell lines in vitro and in vivo. As a result, there has been an emerging interest in the potential role of vitamin D in the etiology of prostate cancer. This review summarizes all available epidemiological literature on the association between dietary vitamin D, circulating levels of vitamin D and sunlight exposure in relation to prostate cancer risk. To place these studies in context, we also provide some background information on vitamin D, such as its dietary sources, metabolism, optimal levels, hypovitaminosis and relationship with the prostate.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Bono AV . The global state of prostate cancer: epidemiology and screening in the second millennium. BJU Int 2004; 94 (Suppl 3): 1–2.

    PubMed  Google Scholar 

  2. Brawley OW, Barnes S . The epidemiology of prostate cancer in the United States. Semin Oncol Nurs 2001; 17: 72–77.

    CAS  PubMed  Google Scholar 

  3. Chodak G . Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006; 8 (Suppl 2): S3–S8.

    PubMed  PubMed Central  Google Scholar 

  4. Damber JE . Prostate cancer: epidemiology and risk factors. Curr Opin Urol 1998; 8: 375–380.

    CAS  PubMed  Google Scholar 

  5. Gronberg H . Prostate cancer epidemiology. Lancet 2003; 361: 859–864.

    PubMed  Google Scholar 

  6. Hsing AW, Chokkalingam AP . Prostate cancer epidemiology. Front Biosci 2006; 11: 1388–1413.

    CAS  PubMed  Google Scholar 

  7. Scardino PT, Weaver R, Hudson MA . Early detection of prostate cancer. Hum Pathol 1992; 23: 211–222.

    CAS  PubMed  Google Scholar 

  8. Trinchieri A, Moretti R . Trends in prostate cancer epidemiology in the year 2000. Arch Ital Urol Androl 2005; 77: 164–166.

    PubMed  Google Scholar 

  9. Wilt TJ . Prostate cancer: epidemiology and screening. Rev Urol 2003; 5 (Suppl 6): S3–S9.

    PubMed  PubMed Central  Google Scholar 

  10. Ruijter E, van de KC, Miller G, Ruiter D, Debruyne F, Schalken J . Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22–45.

    CAS  PubMed  Google Scholar 

  11. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case–control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795–804.

    CAS  PubMed  Google Scholar 

  12. Lee MM, Wang RT, Hsing AW, Gu FL, Wang T, Spitz M . Case–control study of diet and prostate cancer in China. Cancer Causes Control 1998; 9: 545–552.

    CAS  PubMed  Google Scholar 

  13. Veierod MB, Laake P, Thelle DS . Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997; 73: 634–638.

    CAS  PubMed  Google Scholar 

  14. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571–1579.

    CAS  PubMed  Google Scholar 

  15. Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25–34.

    CAS  PubMed  Google Scholar 

  16. Nomura AM, Kolonel LN . Prostate cancer: a current perspective. Epidemiol Rev 1991; 13: 200–227.

    CAS  PubMed  Google Scholar 

  17. Brawn PN, Johnson EH, Kuhl DL, Riggs MW, Speights VO, Johnson CF et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993; 71: 2569–2573.

    CAS  PubMed  Google Scholar 

  18. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S . Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000; 82: 1585–1592.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Ogunbiyi JO, Shittu OB . Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc 1999; 91: 159–164.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Osegbe DN . Prostate cancer in Nigerians: facts and nonfacts. J Urol 1997; 157: 1340–1343.

    CAS  PubMed  Google Scholar 

  21. Buschemeyer III WC, Freedland SJ . Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331–343.

    PubMed  Google Scholar 

  22. Hanchette CL, Schwartz GG . Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861–2869.

    CAS  PubMed  Google Scholar 

  23. Routh JC, Leibovich BC . Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005; 80: 899–907.

    PubMed  Google Scholar 

  24. Dennis LK, Hayes RB . Alcohol and prostate cancer. Epidemiol Rev 2001; 23: 110–114.

    CAS  PubMed  Google Scholar 

  25. John EM, Dreon DM, Koo J, Schwartz GG . Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89–90: 549–552.

    PubMed  Google Scholar 

  26. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA . Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470–5479.

    CAS  PubMed  Google Scholar 

  27. John EM, Koo J, Schwartz GG . Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev 2007; 16: 1283–1286.

    PubMed  Google Scholar 

  28. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641–642.

    CAS  PubMed  Google Scholar 

  29. Ekman P, Pan Y, Li C, Dich J . Environmental and genetic factors: a possible link with prostate cancer. Br J Urol 1997; 79 (Suppl 3): 35–41.

    PubMed  Google Scholar 

  30. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW . Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995; 6: 235–239.

    CAS  PubMed  Google Scholar 

  31. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.

    CAS  PubMed  Google Scholar 

  32. Gronberg H, Damber L, Damber JE . Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152: 1484–1487.

    CAS  PubMed  Google Scholar 

  33. Krain LS . Some epidemiologic variables in prostatic carcinoma in California. Prev Med 1974; 3: 154–159.

    CAS  PubMed  Google Scholar 

  34. Woolf CM . An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739–744.

    CAS  PubMed  Google Scholar 

  35. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P . Family history of prostate cancer: a multi-center case–control study in Canada. Int J Cancer 1997; 70: 679–681.

    CAS  PubMed  Google Scholar 

  36. Hickey K, Do KA, Green A . Smoking and prostate cancer. Epidemiol Rev 2001; 23: 115–125.

    CAS  PubMed  Google Scholar 

  37. Peterson HB, Howards SS . Vasectomy and prostate cancer: the evidence to date. Fertil Steril 1998; 70: 201–203.

    CAS  PubMed  Google Scholar 

  38. Lee IM, Sesso HD, Chen JJ, Paffenbarger Jr RS . Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev 2001; 23: 132–137.

    CAS  PubMed  Google Scholar 

  39. Blutt SE, Weigel NL . Vitamin D and prostate cancer. Proc Soc Exp Biol Med 1999; 221: 89–98.

    CAS  PubMed  Google Scholar 

  40. Feldman D, Zhao XY, Krishnan AV . Vitamin D and prostate cancer. Endocrinology 2000; 141: 5–9.

    CAS  PubMed  Google Scholar 

  41. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM . Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 1996; 223: 141–146.

    CAS  PubMed  Google Scholar 

  42. Strugnell SA, Deluca HF . The vitamin D receptor—structure and transcriptional activation. Proc Soc Exp Biol Med 1997; 215: 223–228.

    CAS  PubMed  Google Scholar 

  43. Wang X, Chen X, Akhter J, Morris DL . The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Br J Urol 1997; 80: 260–262.

    CAS  PubMed  Google Scholar 

  44. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL . Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997; 126: 83–90.

    CAS  PubMed  Google Scholar 

  45. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP . 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6: 727–732.

    CAS  PubMed  Google Scholar 

  46. Skowronski RJ, Peehl DM, Feldman D . Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952–1960.

    CAS  PubMed  Google Scholar 

  47. Zhuang SH, Burnstein KL . Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998; 139: 1197–1207.

    CAS  PubMed  Google Scholar 

  48. Gross C, Stamey T, Hancock S, Feldman D . Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035–2039.

    CAS  PubMed  Google Scholar 

  49. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ . Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003; 133: 2425S–2433S.

    CAS  PubMed  Google Scholar 

  50. Giovannucci E . The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005; 16: 83–95.

    PubMed  Google Scholar 

  51. Holick MF . Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 2008; 3: 1548–1554.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R . Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68: 854–858.

    CAS  PubMed  Google Scholar 

  53. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86:888–894.

    CAS  PubMed  Google Scholar 

  54. Mehta RG, Mehta RR . Vitamin D and cancer. J Nutr Biochem 2002; 13: 252–264.

    CAS  PubMed  Google Scholar 

  55. Nishimura A, Shinki T, Jin CH, Ohyama Y, Noshiro M, Okuda K et al. Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 1994; 134: 1794–1799.

    CAS  PubMed  Google Scholar 

  56. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA . Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108–4110.

    CAS  PubMed  Google Scholar 

  57. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R . Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713–716.

    CAS  PubMed  Google Scholar 

  58. Hollis BW . Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317–322.

    CAS  PubMed  Google Scholar 

  59. Bischoff-Ferrari HA . Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008; 624: 55–71.

    CAS  PubMed  Google Scholar 

  60. Lips P . Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477–501.

    CAS  PubMed  Google Scholar 

  61. McKenna MJ . Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992; 93: 69–77.

    CAS  PubMed  Google Scholar 

  62. Das G, Crocombe S, McGrath M, Berry JL, Mughal MZ . Hypovitaminosis D among healthy adolescent girls attending an inner city school. Arch Dis Child 2006; 91: 569–572.

    CAS  PubMed  Google Scholar 

  63. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212–1221.

    CAS  PubMed  Google Scholar 

  64. Sullivan SS, Rosen CJ, Halteman WA, Chen TC, Holick MF . Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc 2005; 105: 971–974.

    CAS  PubMed  Google Scholar 

  65. Yanoff LB, Parikh SJ, Spitalnik A, Denkinger B, Sebring NG, Slaughter P et al. The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf) 2006; 64: 523–529.

    CAS  Google Scholar 

  66. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S . Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 1985; 76: 370–373.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS . 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69–77.

    CAS  PubMed  Google Scholar 

  68. Chatfield SM, Brand C, Ebeling PR, Russell DM . Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J 2007; 37: 377–382.

    CAS  PubMed  Google Scholar 

  69. Olmez D, Bober E, Buyukgebiz A, Cimrin D . The frequency of vitamin D insufficiency in healthy female adolescents. Acta Paediatr 2006; 95: 1266–1269.

    PubMed  Google Scholar 

  70. Goswami R, Gupta N, Goswami D, Marwaha RK, Tandon N, Kochupillai N . Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. Am J Clin Nutr 2000; 72: 472–475.

    CAS  PubMed  Google Scholar 

  71. Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS . Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 2005; 98: 667–676.

    CAS  PubMed  Google Scholar 

  72. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S . Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577–582.

    CAS  PubMed  Google Scholar 

  73. Plotnikoff GA, Quigley JM . Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78: 1463–1470.

    PubMed  Google Scholar 

  74. Rovner AJ, O'Brien KO . Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med 2008; 162: 513–519.

    PubMed  Google Scholar 

  75. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ . Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158: 531–537.

    PubMed  Google Scholar 

  76. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR . Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30: 771–777.

    CAS  PubMed  Google Scholar 

  77. Tangpricha V, Pearce EN, Chen TC, Holick MF . Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112: 659–662.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P . Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 847–852.

    CAS  PubMed  Google Scholar 

  79. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 1992; 52: 515–520.

    CAS  PubMed  Google Scholar 

  80. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P . Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000; 86: 40–46.

    CAS  PubMed  Google Scholar 

  81. Tsai MJ, O'Malley BW . Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451–486.

    CAS  PubMed  Google Scholar 

  82. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR . Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001; 2: 203–216.

    CAS  PubMed  Google Scholar 

  83. Zhao XY, Ly LH, Peehl DM, Feldman D . Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140: 1205–1212.

    CAS  PubMed  Google Scholar 

  84. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP . 5,6-Trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 1999; 59: 4023–4029.

    CAS  PubMed  Google Scholar 

  85. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S . Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996; 1: 97–101.

    CAS  PubMed  Google Scholar 

  86. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652–661.

    CAS  PubMed  Google Scholar 

  87. De Stefani E, Deneo-Pellegrini H, Boffetta P, Ronco A, Mendilaharsu M . Alpha-linolenic acid and risk of prostate cancer: a case–control study in Uruguay. Cancer Epidemiol Biomarkers Prev 2000; 9: 335–338.

    CAS  PubMed  Google Scholar 

  88. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ . Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994; 86: 281–286.

    CAS  PubMed  Google Scholar 

  89. Godley PA, Campbell MK, Miller C, Gallagher P, Martinson FE, Mohler JL et al. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996; 5: 115–119.

    CAS  PubMed  Google Scholar 

  90. Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L . Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 1997; 71: 545–551.

    CAS  PubMed  Google Scholar 

  91. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A . Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9: 559–566.

    CAS  PubMed  Google Scholar 

  92. Grant WB . Calcium, lycopene, vitamin D and prostate cancer. Prostate 2000; 42: 243.

    CAS  PubMed  Google Scholar 

  93. Schwartz GG, Hulka BS . Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10: 1307–1311.

    CAS  PubMed  Google Scholar 

  94. Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000; 11: 859–867.

    CAS  PubMed  Google Scholar 

  95. Tavani A, Bertuccio P, Bosetti C, Talamini R, Negri E, Franceschi S et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005; 48: 27–33.

    CAS  PubMed  Google Scholar 

  96. Tseng M, Breslow RA, Graubard BI, Ziegler RG . Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005; 81: 1147–1154.

    CAS  PubMed  Google Scholar 

  97. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN . Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007; 166: 1259–1269.

    PubMed  Google Scholar 

  98. Huncharek M, Muscat J, Kupelnick B . Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 2008; 60: 421–441.

    PubMed  Google Scholar 

  99. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16: 2623–2630.

    CAS  PubMed  Google Scholar 

  100. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002; 60: 1118–1123.

    PubMed  Google Scholar 

  101. Kristal AR, Cohen JH, Qu P, Stanford JL . Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 719–725.

    CAS  PubMed  Google Scholar 

  102. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: e103.

    PubMed  PubMed Central  Google Scholar 

  103. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998; 9: 425–432.

    CAS  PubMed  Google Scholar 

  104. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N et al. Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst 2008; 100: 796–804.

    CAS  PubMed  Google Scholar 

  105. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E . Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15: 255–265.

    PubMed  Google Scholar 

  106. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer 2004; 108: 104–108.

    CAS  PubMed  Google Scholar 

  107. Clemens TL, Adams JS, Henderson SL, Holick MF . Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1: 74–76.

    CAS  PubMed  Google Scholar 

  108. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ . Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121–126.

    CAS  PubMed  Google Scholar 

  109. Lund B, Sorensen OH . Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population. Scand J Clin Lab Invest 1979; 39: 23–30.

    CAS  PubMed  Google Scholar 

  110. McLaughlin M, Raggatt PR, Fairney A, Brown DJ, Lester E, Wills MR . Seasonal variations in serum 25-hydroxycholecalciferol in healthy people. Lancet 1974; 1: 536–538.

    CAS  PubMed  Google Scholar 

  111. Stamp TC, Round JM . Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 1974; 247: 563–565.

    CAS  PubMed  Google Scholar 

  112. Robsahm TE, Tretli S, Dahlback A, Moan J . Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15: 149–158.

    PubMed  Google Scholar 

  113. Walsh PC . Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Urol 2005; 173: 87.

    PubMed  Google Scholar 

  114. Schwartz GG . Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology 1992; 11: 244–254.

    CAS  PubMed  Google Scholar 

  115. Rukin NJ, Zeegers MP, Ramachandran S, Luscombe CJ, Liu S, Saxby M et al. A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma. Br J Cancer 2007; 96: 523–528.

    CAS  PubMed  PubMed Central  Google Scholar 

  116. de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW . Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol 2007; 165: 966–972.

    PubMed  Google Scholar 

  117. Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer 2007; 43: 1701–1712.

    CAS  PubMed  Google Scholar 

  118. Colli JL, Grant WB . Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology 2008; 71: 531–535.

    PubMed  Google Scholar 

  119. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen 2004; 43: 121–127.

    CAS  PubMed  Google Scholar 

  120. Moon SJ, Fryer AA, Strange RC . Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res 2005; 571: 207–219.

    CAS  PubMed  Google Scholar 

  121. Bodiwala D, Luscombe CJ, Liu S, Saxby M, French M, Jones PW et al. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett 2003; 192: 145–149.

    CAS  PubMed  Google Scholar 

  122. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001; 85: 1504–1509.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Mucci LA, Spiegelman D . Vitamin D and prostate cancer risk—a less sunny outlook? J Natl Cancer Inst 2008; 100: 759–761.

    PubMed  Google Scholar 

  124. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 2005; 14: 586–589.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by Cancer Treatment Centers of America®.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Gupta.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gupta, D., Lammersfeld, C., Trukova, K. et al. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 12, 215–226 (2009). https://doi.org/10.1038/pcan.2009.7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.7

Keywords

  • vitamin D
  • sunlight
  • risk

Further reading

Search

Quick links